 Insulin Lispro
"Insulin Lispro" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Insulin that has been modified so that the B-chain contains a LYSINE at position 28 instead of a PROLINE and a PROLINE at position 29 instead of a LYSINE. It is used to manage BLOOD GLUCOSE levels in patients with TYPE 2 DIABETES.
| Descriptor ID |
D061268
|
| MeSH Number(s) |
D06.472.699.587.200.400.500 D12.644.548.586.200.400.500
|
| Concept/Terms |
Insulin Lispro- Insulin Lispro
- Lispro, Insulin
- 28(B)-Lys-29(B)-Pro-Insulin
- 28(B)-Lysine-29(B)-Prolineinsulin
- Insulin, Lysyl(28B)-Prolyl(28B)-
- Lispro
- LYSPRO
- Insulin, Lys(28B)-Pro(29B)-
|
Below are MeSH descriptors whose meaning is more general than "Insulin Lispro".
Below are MeSH descriptors whose meaning is more specific than "Insulin Lispro".
This graph shows the total number of publications written about "Insulin Lispro" by people in this website by year, and whether "Insulin Lispro" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 | | 2001 | 0 | 1 | 1 | | 2003 | 0 | 2 | 2 | | 2004 | 0 | 2 | 2 | | 2005 | 0 | 1 | 1 | | 2006 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2010 | 0 | 2 | 2 | | 2011 | 1 | 0 | 1 | | 2014 | 2 | 0 | 2 | | 2016 | 1 | 0 | 1 | | 2017 | 1 | 0 | 1 | | 2018 | 2 | 0 | 2 | | 2020 | 1 | 0 | 1 | | 2022 | 1 | 4 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Insulin Lispro" by people in Profiles.
-
Messer LH, Buckingham BA, Cogen F, Daniels M, Forlenza G, Jafri RZ, Mauras N, Muir A, Wadwa RP, White PC, Russell SJ, Damiano ER, El-Khatib FH, Ruedy KJ, Balliro CA, Li Z, Marak MC, Calhoun P, Beck RW. Positive Impact of the Bionic Pancreas on Diabetes Control in Youth 6-17 Years Old with Type 1 Diabetes: A Multicenter Randomized Trial. Diabetes Technol Ther. 2022 10; 24(10):712-725.
-
Russell SJ, Beck RW, Damiano ER, El-Khatib FH, Ruedy KJ, Balliro CA, Li Z, Calhoun P, Wadwa RP, Buckingham B, Zhou K, Daniels M, Raskin P, White PC, Lynch J, Pettus J, Hirsch IB, Goland R, Buse JB, Kruger D, Mauras N, Muir A, McGill JB, Cogen F, Weissberg-Benchell J, Sherwood JS, Castellanos LE, Hillard MA, Tuffaha M, Putman MS, Sands MY, Forlenza G, Slover R, Messer LH, Cobry E, Shah VN, Polsky S, Lal R, Ekhlaspour L, Hughes MS, Basina M, Hatipoglu B, Olansky L, Bhangoo A, Forghani N, Kashmiri H, Sutton F, Choudhary A, Penn J, Jafri R, Rayas M, Escaname E, Kerr C, Favela-Prezas R, Boeder S, Trikudanathan S, Williams KM, Leibel N, Kirkman MS, Bergamo K, Klein KR, Dostou JM, Machineni S, Young LA, Diner JC, Bhan A, Jones JK, Benson M, Bird K, Englert K, Permuy J, Cossen K, Felner E, Salam M, Silverstein JM, Adamson S, Cedeno A, Meighan S, Dauber A. Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. N Engl J Med. 2022 09 29; 387(13):1161-1172.
-
Wadwa RP, Laffel LM, Franco DR, Dellva MA, Knights AW, Pollom RK. Efficacy and safety of ultra-rapid lispro versus lispro in children and adolescents with type 1 diabetes: The PRONTO-Peds trial. Diabetes Obes Metab. 2023 01; 25(1):89-97.
-
Weinstock RS, Bode BW, Garg SK, Klonoff DC, El Sanadi C, Geho WB, Muchmore DB, Penn MS. Reduced hypoglycaemia using liver-targeted insulin in individuals with type 1 diabetes. Diabetes Obes Metab. 2022 09; 24(9):1762-1769.
-
Brazg R, Garg SK, Bhargava A, Thrasher JR, Latif K, Bode BW, Bailey TS, Horowitz BS, Cavale A, Kudva YC, Kaiserman KB, Grunberger G, Reed JC, Chattaraj S, Zhang G, Shin J, Chen V, Lee SW, Cordero TL, Rhinehart AS, Vigersky RA, Buckingham BA. Evaluation of Extended Infusion Set Performance in Adults with Type 1 Diabetes: Infusion Set Survival Rate and Glycemic Outcomes from a Pivotal Trial. Diabetes Technol Ther. 2022 08; 24(8):535-543.
-
Bode BW, Garg SK, Norwood P, Morales C, Hardy T, Liu R, Ignaut D. Compatibility and Safety of Ultra Rapid Lispro with Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: PRONTO-Pump Study. Diabetes Technol Ther. 2021 01; 23(1):41-50.
-
Home P, Derwahl KM, Ziemen M, Wernicke-Panten K, Pierre S, Kirchhein Y, Garg SK. Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes. Diabetes Technol Ther. 2018 02; 20(2):160-170.
-
Thrasher J, Surks H, Nowotny I, Pierre S, Rotthaeuser B, Wernicke-Panten K, Garg S. Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump. J Diabetes Sci Technol. 2018 05; 12(3):680-686.
-
Garg SK, Wernicke-Panten K, Rojeski M, Pierre S, Kirchhein Y, Jedynasty K. Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine-SORELLA 1 Study. Diabetes Technol Ther. 2017 09; 19(9):516-526.
-
Nguyen KV, Weidner JA, Shaw KF, Valdez CA. Converting U-500 regular insulin to insulin detemir and insulin lispro in a patient undergoing dietary changes in preparation for bariatric surgery. Am J Health Syst Pharm. 2016 Mar 01; 73(5):292-7.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|